Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 17 Show results per page	View Search Criteria \| Help With Results


1.		The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Diagnostic				Active				18 and over				Other				FLT-PET CRC-LM NCT00145665


2.		A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				OSI3926g ML20773, NCT00453362


3.		Assessment of 18FLT PET-CT for Volume Definition of High-Grade Gliomas (GLIO-TEP)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Diagnostic				Active				Over 18				Other				9420-04 2004-033, NCT00624728

Last Modified: 8/23/2008 First Published: 11/14/2007


4.		Phase II Study of the Effect of Zoledronic Acid on Standardized Uptake Value By Positron Emission Tomography in Patients With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Diagnostic				Active				18 and over				NCI				WSU-2006-136 2006-136, NCT00559897

Last Modified: 8/29/2008 First Published: 11/29/2007


5.		Phase II Study of 3'-deoxy-3'-18F Fluorothymidine Positron Emission Tomography/CT Scanning in Patients Undergoing Treatment for Stage IIIA, IIIB, or IIIC Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Diagnostic, Treatment				Active				18 and over				NCI				MCV-HM11081 HM11081, 8029, NCT00566293


6.		Erlotinib and Sequential PET in Advanced Non Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Diagnostic, Treatment				Active				18 and over				Other				2005-005393-73 06159, NCT00568841


7.		F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Diagnostic				Active				18 and over				NCI, Other				200801758 1R21CA130281, NCT00721799

First Published: 9/19/2008


8.		Phase II Pilot Study of 3'-deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiotherapy in Patients With Advanced Squamous Cell Carcinoma of the Oropharynx, Larynx, or Hypopharynx

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Diagnostic, Treatment				Approved-not yet active				18 and over				NCI				MAYO-MC057M MC057M, NCT00757549, MAYO-08-002166


9.		Validation of 18F-MISO-PET and 18F-FLT-PET

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Diagnostic, Treatment				Active				Over 18				Other				100 NCT00159978

Last Modified: 10/9/2007 First Published: 7/6/2007


10.		Phase I Study of Sunitinib Malate in Patients With Unresectable or Metastatic Clear Cell Renal Cell Carcinoma or Other Advanced Solid Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				WCCC-CO-06902 CO 06902, 7898, NCT00499135

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute